



PATENTS
Atty. Docket No. HYZ-050CP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sudhir Agrawal

Serial No.: 09/412,947

Filing Date: October 5, 1999

Title: **Modified Protein Kinase A- Specific
Oligonucleotides and Methods of Their
Use**

Art Unit: 1635

Examiner: Epps, J.

Box CPA

Assistant Commissioner for Patents
Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. § 1.97, Applicant and their legal representatives hereby make of record the following references which are known by them and considered warranting disclosure under 37 C.F.R. § 1.56. Copies of all references have been previously submitted. Copies of those references not listed below were previously submitted with the Supplemental Information Disclosure Statements filed on October 17, 2001 and December 3, 2001. However, Applicant will provide additional copies of these references upon request.

The following references were submitted as appendices to the Amendment filed October 17, 2001.

- Milner et al. (1997) "Selecting Effective Antisense Reagents On Combinatorial Oligonucleotide Arrays," *Nature Biotech.* 15:537-541
- Monia et al. (1996) "Antitumor Activity of a Phosphorothioate Antisense Oligodeoxynucleotide Targeted Against C-raf Kinase," *Nature Med.* 2(6):668-675
- Agrawal (ed.) "Antisense Therapeutics," *Meth. in Mol. Medicine* Preface v, Humana Press, New Jersey (1996)

03/20/2002 CNGUYEN 00000014 080219 09412947

04 FC:126 180.00 CH

BOSTON 1380212v2

EXPRESS MAIL LABEL NO. EVO38244798 US

DATE OF DEPOSIT March 18, 2002

- Zamecnik, Agrawal (ed.) "Antisense Therapeutics," *Meth. in Mol. Medicine* p. 6, Humana Press, New Jersey (1996)
- Craig et al. (1997) "Patent Strategies in the Antisense Oligonucleotide Based Therapeutic Approach," *Exp. Opin. Ther. Patents* 7(10):1175-1182

Furthermore, for the following references, the English abstracts only were provided:

- DE 41 10 085 A1 October 1, 1992
- WO 94/13685 June 23, 1994

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

This Supplemental Information Disclosure Statement is being filed concurrently with a request for Continued Prosecution Application. Please charge our Deposit Account No. 08-0219 the \$180.00 fee for this purpose.

If there are any questions, please call the undersigned at the telephone number indicated below.

Respectfully submitted,

HALE AND DORR LLP

March 18, 2002



Ann-Louise Kerner, Ph.D.
Registration No. 33,523
Attorney for Applicants

60 State Street
Boston, MA 02109
(617) 526-6192
(617) 526-5000 (fax)